Literature DB >> 29924369

Precision oncology in the era of radiogenomics: the case of D-2HG as an imaging biomarker for mutant IDH gliomas.

Ovidiu C Andronesi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29924369      PMCID： PMC6007304          DOI： 10.1093/neuonc/noy085

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

1.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

Authors:  Changho Choi; Jack M Raisanen; Sandeep K Ganji; Song Zhang; Sarah S McNeil; Zhongxu An; Akshay Madan; Kimmo J Hatanpaa; Vamsidhara Vemireddy; Christie A Sheppard; Dwight Oliver; Keith M Hulsey; Vivek Tiwari; Tomoyuki Mashimo; James Battiste; Samuel Barnett; Christopher J Madden; Toral R Patel; Edward Pan; Craig R Malloy; Bruce E Mickey; Robert M Bachoo; Elizabeth A Maher
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

2.  Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.

Authors:  Anna Tietze; Changho Choi; Bruce Mickey; Elizabeth A Maher; Benedicte Parm Ulhøi; Ryan Sangill; Yasmin Lassen-Ramshad; Slavka Lukacova; Leif Østergaard; Gorm von Oettingen
Journal:  J Neurosurg       Date:  2017-03-03       Impact factor: 5.115

3.  Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Authors:  Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen
Journal:  Sci Transl Med       Date:  2012-01-11       Impact factor: 17.956

Review 4.  Radiomics, Metabolic, and Molecular MRI for Brain Tumors.

Authors:  Philipp Kickingereder; Ovidiu Cristian Andronesi
Journal:  Semin Neurol       Date:  2018-03-16       Impact factor: 3.420

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Authors:  Ovidiu C Andronesi; Franziska Loebel; Wolfgang Bogner; Małgorzata Marjańska; Matthew G Vander Heiden; A John Iafrate; Jorg Dietrich; Tracy T Batchelor; Elizabeth R Gerstner; William G Kaelin; Andrew S Chi; Bruce R Rosen; Daniel P Cahill
Journal:  Clin Cancer Res       Date:  2015-11-03       Impact factor: 12.531

7.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

8.  Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging.

Authors:  Ken Chang; Harrison X Bai; Hao Zhou; Chang Su; Wenya Linda Bi; Ena Agbodza; Vasileios K Kavouridis; Joeky T Senders; Alessandro Boaro; Andrew Beers; Biqi Zhang; Alexandra Capellini; Weihua Liao; Qin Shen; Xuejun Li; Bo Xiao; Jane Cryan; Shakti Ramkissoon; Lori Ramkissoon; Keith Ligon; Patrick Y Wen; Ranjit S Bindra; John Woo; Omar Arnaout; Elizabeth R Gerstner; Paul J Zhang; Bruce R Rosen; Li Yang; Raymond Y Huang; Jayashree Kalpathy-Cramer
Journal:  Clin Cancer Res       Date:  2017-11-22       Impact factor: 13.801

9.  Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.

Authors:  Francesca Branzoli; Anna Luisa Di Stefano; Laurent Capelle; Chris Ottolenghi; Romain Valabrègue; Dinesh K Deelchand; Franck Bielle; Chiara Villa; Bertrand Baussart; Stéphane Lehéricy; Marc Sanson; Malgorzata Marjanska
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 13.029

10.  Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Authors:  Ovidiu C Andronesi; Isabel C Arrillaga-Romany; K Ina Ly; Wolfgang Bogner; Eva M Ratai; Kara Reitz; A John Iafrate; Jorg Dietrich; Elizabeth R Gerstner; Andrew S Chi; Bruce R Rosen; Patrick Y Wen; Daniel P Cahill; Tracy T Batchelor
Journal:  Nat Commun       Date:  2018-04-16       Impact factor: 14.919
View more
  2 in total

1.  The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Chinmay Sharma; Muhammad Ibrahim; Abhishta Bhandari; Matthew Riggs; Rhondda Jones; Arian Lasocki
Journal:  Neuroradiology       Date:  2021-04-03       Impact factor: 2.804

Review 2.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.